Skip to main content
. 2017 Dec 17;9(4):4451–4460. doi: 10.18632/oncotarget.23377

Figure 4. Survival analysis of PDAC patients with differential let-7d expression.

Figure 4

(A) Analysis of TCGA data demonstrated that the overall survival of PDAC patients with high let-7d expression was longer than that of patients with low let-7d expression (median overall survival: 24.4 vs. 17.7 months (log-rank test; P = 0.02). (B) Serum let-7d expression could predict the response of PDAC patients to gemcitabine-based chemotherapy.